Last update 07 Feb 2025

UCB Korea Co., Ltd.

Subsidiary Company|
1989|
Seoul, South Korea

Overview

Tags

Nervous System Diseases
Other Diseases
Immune System Diseases
Small molecule drug
Synthetic peptide
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Immune System Diseases2
Neoplasms1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Synthetic peptide1
Monoclonal antibody1
Top 5 TargetCount
SV2A(Synaptic vesicle glycoprotein 2A)1
C5(Complement C5)1
IL-17A x IL-17F1

Related

3
Drugs associated with UCB Korea Co., Ltd.
Zilucoplan
Target
C5
Mechanism
C5 inhibitors
Active Org.
UCB SAUCB SA [+8]
Originator Org.
Ra Pharmaceuticals, Inc.Ra Pharmaceuticals, Inc.
Active Indication
Myasthenia Gravis
Inactive Indication
Amyotrophic Lateral Sclerosis [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date25 Sep 2023
Bimekizumab
Target
IL-17A x IL-17F
Mechanism
IL-17A inhibitors [+1]
Active Org.
UCB Pharma SA [+8]
Originator Org.
UCB SAUCB SA
Active Indication
Hidradenitis Suppurativa [+10]
Inactive Indication
Chronic large plaque psoriasis [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
European Union [+3]
First Approval Date20 Aug 2021
Brivaracetam
Target
SV2A
Mechanism
SV2A modulators
Active Org.
UCB SAUCB SA [+13]
Originator Org.
UCB SAUCB SA
Active Indication
Epilepsy [+3]
Inactive Indication
Drug Resistant Epilepsy [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
European Union [+3]
First Approval Date13 Jan 2016
4
Clinical Trials associated with UCB Korea Co., Ltd.
NCT01523301
/ CompletedPhase 4
Double Blind, Placebo-controlled, Parallel, Multicenter, Randomized Interventional Phase IV Study to Evaluate the Efficacy of Rotigotine on Depressive Symptoms in Idiopathic Parkinson's Disease Patients
NCT01498822
/ CompletedPhase 4
A Multi-Center, Open-label, Randomized Study to Evaluate the Long Term Effectiveness of Levetiracetam as Monotherapy in Comparison With Oxcarbazepine in Subjects With Newly or Recently Diagnosed Partial Epilepsy
NCT02101710
/ CompletedPhase 1
A Randomized, Open-label, One Dose, 2-way Crossover Study to Evaluate the Bioequivalence of Elantan SR* 60 mg in Comparison With Imdur SR* 60 mg Under Fasted and Fed Conditions in Healthy Korean Male Subjects (*Sustained Release)
100 Clinical Results associated with UCB Korea Co., Ltd.
Login to view more data
0 Patents (Medical) associated with UCB Korea Co., Ltd.
Login to view more data
100 Deals associated with UCB Korea Co., Ltd.
Login to view more data
100 Translational Medicine associated with UCB Korea Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 19 Apr 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Zilucoplan
 ( C5 )		Myasthenia Gravis
More
Approved
Bimekizumab
 ( IL-17A x IL-17F )		Plaque psoriasis
More
Approved
Brivaracetam
 ( SV2A )		Epilepsies, Partial
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free